RD_frontpage

Glossary

Discovery research
Basic research to find pathways and molecules

Preclinical phase
Establishing safety in laboratory tests

Phase I
First trials with healthy volunteers to further establish safety and dosage

Phase II
Clinical testing on a limited number of patients to establish proof of concept

Phase III
Large scale clinical testing on patients

Phase IV
Adding new therapeutic indications or improving existing formulations of the drug

MAA
Market Authorisation Application

MRP
Mutual Recognition process

Launch
Currently being launched
Clinical studies running for label extensions

R & D

Together for medicines that matter
Filling the R&D pipeline to create and deliver new therapeutics to patients is a core task for securing future growth. Our R&D teams are dedicated to developing medicines that have a distinct medical utility for patients, physicians or payers.

Our R&D has established a new strategy and operating model that ensures flexibility in working with partners. With this new model, we expect some four-fifths of R&D projects to originate outside the company, before they are in-licensed and co-developed.

From the earliest research stages onward, Nycomed’s R&D is organised to meet specific needs for partnering projects, particularly in its focus areas: respiratory, inflammation/auto-immune, pain, musculosceletal and gastroenterology.